# US 5,707,814 A · CD8.sup.+ cell antiviral factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,707,814 A
- Document ID: US5707814A
- Status: Granted
- Kind: A
- Application number: 08/610,942
- Filed: 1996-03-05
- Granted: 1998-01-13
- Earliest claimed: 1991-11-01
- Assignees: The Regents of the University of California
- Inventors: Jay A. Levy; Carl E. Mackewicz
- Web page: https://patentgrep.com/patent/US5707814A

## CPC

- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A protein secreted by peripheral blood mononuclear cells and specifically from CD8.sup.+ lymphocytes is purified and characterized here and designated CD8.sup.+ cell antiviral factor (CAF). The CAF is lipid free and has been found to inhibit the replication of retroviruses and in particular to inhibit the replication of HIV-1, HIV-2, and SIV. CAF can be used to inhibit viral RNA transcription which inhibits vital replication. Accordingly, CAF can be used to treat patients infected with retroviruses. The CAF can also generate antibodies which can be used to create assay devices for detecting CAF in a body fluid and on the surface of CD8.sup.+ cells to determine the condition of an HIV infected individual.

## Claims

### Claim 1

An antibody which is immunospecific to a CD8.sup.+ cell antiviral factor defined by the following characteristics:
(i) blocks vital replication by inhibiting viral RNA transcription;
(ii) does not effect CD4.sup.+ cell activation or proliferation;
(iii) is not a cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-16, G-CSF, GM-CSF, TNF.alpha., TNF.beta., IFN.alpha., IFN.beta., IFN.gamma., TGF.beta., RANTES, MIP-1.alpha., MIP-1.beta., MCP-1, MCP-3, IP-10, lymphotactin, GRO-.alpha., GRO-.beta., and LIP;
(iv) is not a soluble receptor selected from the group consisting of TNF.alpha.-I receptor and TNF.alpha.-II receptor.

### Claim 2 (depends on 1)

The antibody of claim 1 wherein the antibody is a monoclonal antibody.

### Claim 3 (depends on 1)

The antibody of claim 1 wherein the antibody is bound to a detectable label.

### Claim 4 (depends on 1)

A composition comprising a substrate having bound to its surface antibodies of claim 1.

### Claim 5 (depends on 1)

A method of monitoring the effectiveness of a treatment of an HIV infected individual, comprising:
treating an HIV infected individual by administering to that individual a compound believed to be effective in treating HIV infected individuals;
assaying a body fluid of the individual using an antibody of claim 1; and
determining the effect of the compound on levels of CD8.sup.+ cell antiviral factor or number of CD8.sup.+ lymphocytes having CD8.sup.+ cell antiviral factor on its surface.

### Claim 6 (depends on 5)

The method of claim 5, wherein the body fluid is assayed for levels of CD8.sup.+ cell antiviral factor using monoclonal antibodies by ELISA.

### Claim 7 (depends on 5)

The method of claim 5, wherein the body fluid is assayed for the number of CD8.sup.+ lymphocytes, having CD8.sup.+ antiviral factor on their surface, per unit volume of body fluid using flow cytometry.

### Claim 8 (depends on 1)

A method for detecting the presence of CD8.sup.+ cell antiviral factor on the surface of CD8.sup.+ lymphocytes, comprising:
(a) contacting the antibody of claim 1 with a body fluid containing CD8.sup.+ lymphocytes; and
(b) detecting the binding of the antibodies to cell antiviral factor on the surface of the lymphocytes via flow cytometry.

### Claim 9

A method of inhibiting the replication of retrovirus in cells comprising exposing the cells to a substantially pure composition of CD8.sup.+ cell antiviral factor defined by the following properties:
(a) released from activated CD8.sup.+ cells;
(b) biologically inactivated when exposed to a pH in a range of 10-12 while maintaining biological activity when exposed to a pH in the range of 2-8;
(c) resistant to heat of 100.degree. C. for 30 minutes to the extent that about 60% of its activity is maintained;
(d) resistant to trypsin;
(e) does not affect CD4.sup.+ cell activation or proliferation;
(f) blocks viral replication by inhibiting viral RNA transcription;
(g) function not inhibited by antibodies specific for IFN.alpha., IFN.beta., IFN.gamma., TNF.alpha., TNF.beta., TGF.beta., IL-6, IL-4, MIP-1.alpha., MIP-1.beta. or RANTES;
(h) is not a cytokine selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-16, G-CSF, GM-CSF, TNF.alpha., TNF.beta., IFN.alpha., IFN.beta., IFN.gamma., TGF.beta., RANTES, MIP-1.alpha., MIP-1.beta., MCP-1, MCP-3, IP-10, lymphotactin, GRO-.alpha., GRO-.beta., and LIF;
(i) is not a soluble receptor selected from the group consisting of TNF.alpha.-I receptor and TNF.alpha.-II receptor;
(j) activity is maintained after being subjected to freezing and thawing;
(k) sensitive to staph V8 protease but not to protease type XIA (proteinase K);
(l) does not induce 2'-5'-A synthetase in CD4.sup.+ lymphocytes and is, accordingly, different from interferon;
(m) precipitated from CD8.sup.+ cell supernatant by 53% ammonium sulfate;
(n) lipid free; and
wherein substantially pure indicates that any of the cytokines of (h) naturally present in CD8.sup.+ cell extract as well as any soluble receptor of (i) naturally present in CD8.sup.+ cell extract have been separated away.